NCCN Added Brigatinib to Schwannomatosis Guidelines
The latest cancer treatment guidelines now include this drug as a recommended therapy for NF2-related schwannomatosis.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Do you believe updated clinical guidelines increase your trust in standard medical treatment options?
The National Comprehensive Cancer Network updated its Clinical Practice Guidelines in Oncology to include brigatinib as a recommended treatment for NF2-related schwannomatosis. This change establishes a new standard for clinicians and helps facilitate the insurance approval process for patients.
Why it matters
Updating these national guidelines helps community oncologists adopt new standards of care and provides a necessary reference point for insurers. This transition streamlines access to specialized treatment for individuals living with this complex condition.
The National Comprehensive Cancer Network officially updated its Clinical Practice Guidelines in Oncology for Central Nervous System Cancers to include brigatinib. This recommendation serves as an evidence-based standard for managing NF2-related schwannomatosis.
The players
National Comprehensive Cancer Network
A non-profit alliance of leading cancer centers that develops clinical practice guidelines to define and improve the quality of cancer care.
The details
Brigatinib is a tyrosine kinase inhibitor (TKI) known as Alunbrig that works by targeting specific cellular pathways. Because the therapy can cause side effects such as fatigue, muscle soreness, gastrointestinal issues, and elevated creatine kinase levels, physicians monitor patients using complete metabolic panels and regular blood count checks. Patients are typically scheduled for monthly check-ins early in the treatment course to manage these potential adverse effects.
Timeline
September 28, 2026: The NCCN published the updated guidelines for Central Nervous System Cancers.
Health Landscape
This update aligns with the ongoing expansion of the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology to include targeted TKIs. It reflects the broader trend of integrating precision medicine approaches into the standard of care for rare tumor syndromes.
Patients with NF2-related schwannomatosis should discuss with their care team whether this new guideline recommendation changes their current treatment plan. Regular monitoring through blood work and monthly appointments remains a critical part of ensuring safety while taking this TKI agent.
The takeaway
The inclusion of brigatinib in national guidelines provides a stronger pathway for patients to access this therapy for schwannomatosis. If you or a loved one are managing this condition, speak with your oncologist about how this updated clinical standard might affect your care strategy.
Further reading
For more information on current treatment standards and care protocols, visit the Cancer section.
Source note: This article includes information reported by OncLive.
Live Poll
Do you believe updated clinical guidelines increase your trust in standard medical treatment options?
